BioHarvest Sciences (BHST) Competitors $7.61 -0.04 (-0.52%) As of 03:56 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock BHST vs. ZVRA, MBX, BCYC, ALMS, EOLS, CMPX, TECX, UPXI, KOD, and ARCTShould you be buying BioHarvest Sciences stock or one of its competitors? The main competitors of BioHarvest Sciences include Zevra Therapeutics (ZVRA), MBX Biosciences (MBX), Bicycle Therapeutics (BCYC), Alumis (ALMS), Evolus (EOLS), Compass Therapeutics (CMPX), Tectonic Therapeutic (TECX), Upexi (UPXI), Kodiak Sciences (KOD), and Arcturus Therapeutics (ARCT). These companies are all part of the "pharmaceutical products" industry. BioHarvest Sciences vs. Its Competitors Zevra Therapeutics MBX Biosciences Bicycle Therapeutics Alumis Evolus Compass Therapeutics Tectonic Therapeutic Upexi Kodiak Sciences Arcturus Therapeutics Zevra Therapeutics (NASDAQ:ZVRA) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings. Do analysts prefer ZVRA or BHST? Zevra Therapeutics presently has a consensus target price of $23.71, suggesting a potential upside of 165.56%. BioHarvest Sciences has a consensus target price of $13.67, suggesting a potential upside of 79.59%. Given Zevra Therapeutics' higher possible upside, equities research analysts clearly believe Zevra Therapeutics is more favorable than BioHarvest Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zevra Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89BioHarvest Sciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings & valuation, ZVRA or BHST? BioHarvest Sciences has higher revenue and earnings than Zevra Therapeutics. Zevra Therapeutics is trading at a lower price-to-earnings ratio than BioHarvest Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZevra Therapeutics$23.61M21.23-$105.51M-$0.21-42.52BioHarvest Sciences$25.19M4.96-$12.91M-$0.70-10.87 Does the media prefer ZVRA or BHST? In the previous week, Zevra Therapeutics had 6 more articles in the media than BioHarvest Sciences. MarketBeat recorded 7 mentions for Zevra Therapeutics and 1 mentions for BioHarvest Sciences. Zevra Therapeutics' average media sentiment score of 0.94 beat BioHarvest Sciences' score of 0.00 indicating that Zevra Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioHarvest Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders have more ownership in ZVRA or BHST? 35.0% of Zevra Therapeutics shares are owned by institutional investors. 2.4% of Zevra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, ZVRA or BHST? Zevra Therapeutics has a beta of 1.56, meaning that its stock price is 56% more volatile than the S&P 500. Comparatively, BioHarvest Sciences has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Is ZVRA or BHST more profitable? Zevra Therapeutics has a net margin of 4.33% compared to BioHarvest Sciences' net margin of -39.95%. Zevra Therapeutics' return on equity of -112.40% beat BioHarvest Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Zevra Therapeutics4.33% -112.40% -37.67% BioHarvest Sciences -39.95%-11,357.84%-39.94% SummaryZevra Therapeutics beats BioHarvest Sciences on 12 of the 16 factors compared between the two stocks. Get BioHarvest Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for BHST and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BHST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BHST vs. The Competition Export to ExcelMetricBioHarvest SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$125.65M$3.13B$5.76B$9.85BDividend YieldN/A2.28%6.71%4.51%P/E Ratio-10.877.5859.1122.53Price / Sales4.96458.96547.00119.09Price / CashN/A44.5237.0558.92Price / Book95.139.9310.916.06Net Income-$12.91M-$53.38M$3.29B$266.28M7 Day Performance-4.40%0.05%0.01%-0.76%1 Month Performance-0.78%7.08%7.06%3.83%1 Year PerformanceN/A11.92%50.09%24.39% BioHarvest Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BHSTBioHarvest SciencesN/A$7.61-0.5%$13.67+79.6%N/A$125.65M$25.19M-10.87N/APositive NewsGap DownZVRAZevra Therapeutics3.1124 of 5 stars$9.07-2.5%$23.71+161.5%+22.2%$522.06M$23.61M-43.1920Short Interest ↑MBXMBX Biosciences2.5816 of 5 stars$15.09+5.7%$37.63+149.3%N/A$506.93MN/A-3.3236News CoverageBCYCBicycle Therapeutics3.364 of 5 stars$7.38+4.2%$22.22+201.1%-65.9%$490.32M$35.28M-2.10240Positive NewsALMSAlumis2.5714 of 5 stars$4.64-1.3%$20.17+334.6%-61.6%$489.10MN/A0.00N/AEOLSEvolus4.5294 of 5 stars$7.63+1.5%$21.25+178.5%-52.6%$486.43M$266.27M-7.79170News CoveragePositive NewsShort Interest ↓CMPXCompass Therapeutics2.696 of 5 stars$3.49flat$12.89+269.3%+123.2%$482.61M$850K-7.7620News CoverageTECXTectonic Therapeutic2.7759 of 5 stars$25.54-0.1%$80.33+214.5%-14.9%$478.47MN/A-6.32120News CoveragePositive NewsAnalyst ForecastUPXIUpexi2.194 of 5 stars$7.23-10.6%$15.50+114.4%+59.5%$474.17M$26M0.00130Gap DownKODKodiak Sciences3.8189 of 5 stars$9.04+0.8%$11.75+30.0%+254.1%$473.81MN/A-2.3890ARCTArcturus Therapeutics3.6569 of 5 stars$17.01-1.7%$50.57+197.3%-11.3%$469.77M$152.31M-7.63180News CoverageAnalyst Forecast Related Companies and Tools Related Companies Zevra Therapeutics Competitors MBX Biosciences Competitors Bicycle Therapeutics Competitors Alumis Competitors Evolus Competitors Compass Therapeutics Competitors Tectonic Therapeutic Competitors Upexi Competitors Kodiak Sciences Competitors Arcturus Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BHST) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is hereWashington just added $1 trillion to the national debt in less than two months — an astonishing pace of spendi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioHarvest Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioHarvest Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
